ASH Clinical News ACN_4.9_Digital_Issue | Page 31

CLINICAL NEWS Conference Coverage BREAKTHROUGHS IN BLOOD DISORDERS he European Hematology Asso- ciation’s 23rd Congress was held June 14-17 in Stockholm, Sweden, where more than 10,000 interna- tional hematologists met to share the lat- est results from clinical and translational research in hematologic disorders and emerging techniques for diagnosis and risk assessment. Here, ASH Clinical News presents highlights from the meeting, including a combination of polatuzumab vedotin, bendamustine, and rituximab in diffuse large B-cell lymphoma and fostamatinib for patients with warm antibody auto- immune hemolytic anemia. Look for more reporting from the con- ference in our August issue. Synthetic Hepcidin Options Safe in Patients With Iron Disorders, But Efficacy Data Still Preliminary Two studies presented at the 23rd Congress of the European Hematology Association examined the safety and pharmacokinetics of two synthetic hepcidin options for the treat- ment of hereditary blood disorders associated with iron overload: PTG-300 and LJPC-401. Hepcidin is secreted by the liver and acts as “the master regulator of serum iron concentrations,” explained one study’s lead author Ashutosh Lal, MD, of the UCSF Benioff Children’s Hospital in San Francisco. “Several disorders of iron overload, such as hereditary hemochromatosis and beta-thalassemia major, are associated with reduced hepcidin secretion, [and] there is considerable interest in augmenting endo- genous hepcidin for the management of iron overload.” LJPC-401 LJPC-401 is a synthetic endogenous human hepcidin that mimics the natural hepcidin hormone. Dr. Lal and colleagues evaluated its safety in a phase I study of 18 patients (7 with hemoglobinopathies and 11 with hemochromatosis), who had the following disorders and medical histories: • transfusion-dependent anemia • iron chelation therapy within 6 months prior to enrollment • serum ferritin >1,000 μg/L • hemochromatosis requiring phlebotomy at least once every 2 months Continued on page 34 ASHClinicalNews.org ASH Clinical News 29